Yazarlar : Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R.

Yayın : Blood.

Yayın Yılı : 2010

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/20693429?dopt=Abstract

Konu : Lösemi

Literatür İçeriği :  Abstract

We conducted a multi-institutional randomized study to determine whether high-dose daunorubicin (DNR) would be as effective as standard-dose idarubicin (IDR) in remission induction therapy for newly diagnosed adult patients aged younger than 65 with acute myeloid leukemia (AML). Of 1,064 patients registered, 1,057 were evaluable. They were randomly assigned to receive either DNR (50 mg/m(2) daily for 5 days) or IDR (12 mg/m(2) daily for 3 days), in combination with 100 mg/m(2) cytarabine by continuous infusion daily for 7 days, as induction therapy. Complete remission (CR) was achieved in 407 (77.5%) of 525 patients in the DNR group and 416 (78.2%) of 532 in the IDR group (P = 0.79). Patients achieving CR received intensive post-remission therapy consisting of either 3 courses of high-dose cytarabine or 4 courses of standard-dose therapy. Overall survival rates at 5 years were 48% for the DNR group and 48% for the IDR group (P = 0.54), and relapse-free survival rates at 5 years were 41% and 41% (P = 0.97), respectively. Thus, high-dose DNR and standard-dose IDR are equally effective for the treatment of adult AML, achieving a high CR rate and good long-term efficacy. This study is registered at http://www.umin.ac.jp/ctrj/ as C000000157.

Literatür Arşivi